Compare Strategy Inc. (MSTR) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Strategy Inc. vs 10X Genomics Inc — how do they compare? Strategy Inc. trades at $133.49 (market cap $54.24B), while 10X Genomics Inc trades at $67.8 (market cap $8.55B). The key difference: Strategy Inc. is far larger — about 6.3× 10X Genomics Inc's market cap, and 10X Genomics Inc is trading nearer its 52-week high, Strategy Inc. nearer its low. Which is the better fit depends on your goals.
| MSTR | TXG | |
|---|---|---|
Market Cap | $54.24B | $8.55B |
Sector | Technology | Health |
52-Week High | $359.69 | $67.29 |
52-Week Low | $82.31 | $11.34 |
Enterprise Value | $73.00B | $8.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTR trades at $136.52, down 4.4% on the day, with a bullish technical signal from moving averages. The company reported Q2 2026 EPS of -$24.45, missing estimates, and has a negative net income margin of -6,102.96%. Recent news highlights a $176.3 million preferred stock buyback instead of Bitcoin purchases, and a partnership with Google Cloud for an AI forum series.
The outlook is mixed: analyst consensus is bullish with a $229.64 price target, but significant risks include persistent earnings misses, high debt, and negative profitability. The stock's performance is heavily tied to Bitcoin market sentiment, posing volatility risks despite institutional interest.
TXG trades at $65.60, up 4.71% today, with strong technical momentum showing bullish moving averages and key support at $63. Fundamentally, the company demonstrates improving trends with Q2 2026 earnings beating estimates and revenue growth guidance raised, though profitability remains negative with a -12.18% net margin. Recent patent victory against Parse Biosciences strengthens competitive positioning.
The outlook remains cautiously optimistic with analyst consensus at 45% buy ratings and $50.78 price target. Key opportunities include Atera platform adoption and consumables growth, while risks center on valuation premiums and ongoing profitability challenges. The stock trades near resistance at $67 with institutional interest showing mixed signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Strategy Inc.
MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web
Read more on MSTR →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
